News Flash

Neupro Patch for Parkinson's Patients Recalled

Source: The Food and Drug Administration

Neupro, a transdermal patch, used to treat early stage Parkinson’s disease, has been recalled because of a crystalization problem.  When the drug crystallizes, it it not absorbed through the skin at the correct rate, making it less effective.

Healthcare professionals should not prescribe Neupro to any new patients, and should begin transitioning patients to other drugs using the guidelines in the product labeling. Patients should NOT abruptly discontinue therapy. Abrupt withdrawal can be life-threatening.

The following Web sites contain additional information for patients and physicians:
Patients: http://www.fda.gov/cder/drug/shortages/Neupro_US_Patients.pdf
Physicians: http://www.fda.gov/cder/drug/shortages/Neupro_US_Physicians.pdf

Read the complete 2008 MedWatch Safety Summary, including a link to the FDA's Drug Shortage Information Sheet regarding this issue at:  http://www.fda.gov/medwatch/safety/2008/safety08.htm#neupro